Tong Lu Selected Research

polatuzumab vedotin

12/2020	Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
12/2020	Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
1/2020	Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
1/2020	Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.
1/2020	Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tong Lu Research Topics

Disease

36	Neoplasms (Cancer) 06/2022 - 01/2012
12	Adenocarcinoma of Lung 06/2022 - 01/2018
7	Insulin Resistance 12/2018 - 07/2003
5	Carcinogenesis 04/2021 - 01/2018
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 01/2018
5	Obesity 10/2004 - 07/2003
4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 12/2019
4	Neoplasm Metastasis (Metastasis) 04/2021 - 01/2015
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2020 - 01/2020
4	Type 2 Diabetes Mellitus (MODY) 12/2018 - 01/2004
4	Diabetes Mellitus 07/2012 - 12/2008
3	Lung Neoplasms (Lung Cancer) 03/2022 - 09/2012
3	Fibrosis (Cirrhosis) 01/2022 - 02/2006
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2021 - 12/2019
3	Breast Neoplasms (Breast Cancer) 01/2021 - 04/2016
2	Hypertension (High Blood Pressure) 01/2022 - 10/2016
2	Residual Neoplasm 01/2022 - 12/2021
2	Esophageal Squamous Cell Carcinoma 01/2022 - 06/2021
2	Atrial Remodeling 12/2021 - 06/2017
2	Gastroparesis 08/2021 - 01/2021
2	Allergic Rhinitis 01/2021 - 01/2019
2	Necrosis 10/2020 - 07/2010
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 12/2019
2	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 01/2015
2	Chronic Renal Insufficiency 01/2019 - 04/2017
2	Body Weight (Weight, Body) 12/2018 - 10/2017
2	Hyperglycemia 09/2006 - 07/2004
2	Glucose Intolerance 08/2005 - 05/2005
1	Melanoma (Melanoma, Malignant) 01/2022
1	Ureteral Obstruction 01/2022
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022
1	Hemorrhage 01/2022
1	Rheumatoid Arthritis 01/2022
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022
1	Nausea 01/2021
1	COVID-19 01/2021
1	Colonic Neoplasms (Colon Cancer) 01/2021
1	Hyperplasia 01/2021

Drug/Important Bio-Agent (IBA)

10	Biomarkers (Surrogate Marker)IBA 06/2022 - 09/2012
9	Proteins (Proteins, Gene)FDA Link 11/2021 - 07/2003
7	Messenger RNA (mRNA)IBA 01/2022 - 07/2003
7	Circular RNAIBA 04/2021 - 01/2018
7	Glucose (Dextrose)FDA LinkGeneric 12/2018 - 03/2004
7	Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)IBA 10/2017 - 09/2006
6	MicroRNAs (MicroRNA)IBA 04/2021 - 06/2017
5	Pharmaceutical PreparationsIBA 06/2022 - 12/2018
5	Rituximab (Mabthera)FDA Link 01/2022 - 12/2019
5	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2020
5	polatuzumab vedotinIBA 12/2020 - 01/2020
4	venetoclaxIBA 01/2022 - 12/2019
4	Biological ProductsIBA 12/2021 - 11/2012
4	EnzymesIBA 10/2021 - 05/2005
3	LipidsIBA 01/2022 - 07/2004
3	Small Interfering RNA (siRNA)IBA 04/2021 - 01/2015
3	Insulin (Novolin)FDA Link 05/2005 - 07/2004
2	Immune Checkpoint InhibitorsIBA 06/2022 - 01/2020
2	Bendamustine Hydrochloride FDA Link 01/2022 - 12/2020
2	mRNA VaccinesIBA 01/2022 - 01/2022
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2021
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 01/2022
2	obinutuzumabIBA 12/2021 - 01/2020
2	Contrast MediaIBA 08/2021 - 11/2019
2	Hematoxylin (Haematoxylon)IBA 01/2021 - 07/2010
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2021 - 07/2010
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 11/2012
2	ErbB Receptors (EGF Receptor)IBA 01/2021 - 09/2019
2	Long Noncoding RNAIBA 01/2021 - 01/2018
2	HhAntag691IBA 01/2021 - 01/2020
2	IronIBA 10/2020 - 11/2012
2	Competitive Endogenous RNAIBA 02/2020 - 01/2019
2	PowdersIBA 11/2019 - 12/2018
2	Endoplasmic Reticulum Chaperone BiPIBA 01/2019 - 01/2015
2	CreatinineIBA 01/2019 - 04/2017
2	Cystatin CIBA 01/2019 - 04/2017
2	Metformin (Glucophage)FDA LinkGeneric 08/2005 - 05/2005
2	Pioglitazone (Actos)FDA Link 08/2005 - 05/2005
1	B7-H1 AntigenIBA 06/2022
1	fibrin fragment D (D-dimer)IBA 03/2022
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 03/2022
1	hinokiflavoneIBA 01/2022
1	Maytansine (Maitansine)IBA 01/2022
1	aristolochic acid I (aristolochic acid)IBA 01/2022
1	BiflavonoidsIBA 01/2022
1	Prostaglandins AIBA 01/2022
1	Cancer VaccinesIBA 01/2022
1	Peptides (Polypeptides)IBA 11/2021
1	Ubiquitinated ProteinsIBA 11/2021
1	antineoplaston A10 (A 10)IBA 04/2021
1	Tumor Biomarkers (Tumor Markers)IBA 01/2021
1	OvalbuminIBA 01/2021
1	Trastuzumab (Herceptin)FDA Link 01/2021
1	LuciferasesIBA 01/2021

Therapy/Procedure

10	Therapeutics 06/2022 - 01/2016
4	Drug Therapy (Chemotherapy) 06/2022 - 04/2016
3	Immunotherapy 06/2022 - 01/2020
2	Aftercare (After-Treatment) 12/2019 - 05/2005
2	Lasers (Laser) 11/2019 - 09/2012
1	Knee Replacement Arthroplasty (Total Knee Replacement) 01/2022
1	Oral Administration 08/2021
1	Intraperitoneal Injections 01/2021